A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens.

Trial Profile

A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2015

At a glance

  • Drugs Beclometasone (Primary) ; Methotrexate; Tacrolimus
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jun 2012 Results published in Biology of Blood and Marrow Transplantation.
    • 28 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Oct 2010 Preliminary results reported in a Soligenix media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top